Saphenous vein graft (SVG) aneurysms (SVGA) after renal transplantation represents a rare vascular complication with subsequent challenging multidisciplinary treatment. We present a case of a 30-year-old female who received a live donor kidney transplantation for end-stage renal disease that was caused due to the hemolytic uremic syndrome. Postoperatively, an insufficient graft perfusion due to an arterial kinking was noted and repaired using an autologous SVG interposition. Ten years later, a 3-cm aneurysm of the SVG at the anastomotic site with the common iliac artery was discovered. Multidisciplinary surgical exploration with excision of the aneurysm-carrying vein graft and interposition of a new autologous SVG was successfully carried out with preservation of renal allograft's function. Treatment of SVGA after rental transplantation with a new autologous SVG is challenging but feasible, requiring a multidisciplinary approach in order to guarantee successful rates and to prevent allograft loss.

Keywords:
Reconstructive surgery, Saphenous vein graft aneurysm, Renal transplantation, Renal artery reconstruction
1.
Dimitroulis D, Bokos J, Zavos G, Nikiteas N, Karidis NP, Katsaronis P, Kostakis A: Vascular complications in renal transplantation: a single-center experience in 1367 renal transplantations and review of the literature. Transplant Proc 2009;41:1609-1614.
2.
Posner M, King A, Brown K, Lee H: Long-Term Experience with Surgical Repair for Transplant Renal Artery Stenosis. Organ Transplantation 1990. Springer, 1991, pp 491-496.
3.
Hansen KJ, Deitch JS, Oskin TC, Ligush J Jr, Craven TE, Dean RH: Renal artery repair: consequence of operative failures. Ann Surg 1998;227:678.
4.
Cochennec F, Riga CV, Allaire E, Cheshire NJ, Hamady M, Jenkins MP, Kobeiter H, Wolfe JN, Becquemin JP, Gibbs RG: Contemporary management of splanchnic and renal artery aneurysms: results of endovascular compared with open surgery from two European vascular centers. Eur J Vasc Endovasc Surg 2011;42:340-346.
5.
Yuan SM, Jing H: A reappraisal of saphenous vein grafting. Ann Saudi Med 2011;31:62-71.
6.
Haberal HB, Tonyali S, Peynircioğlu B, Arici M, Demircin M, Aki FT: Renal autotransplantation with autologous saphenous vein graft in a patient with takayasu arteritis and existing renal artery stent in her solitary kidney. Urol Int 2017, Epub ahead of print.
7.
Stanley JC, Ernst CB, Fry WJ: Fate of 100 aortorenal vein grafts: characteristics of late graft expansion, aneurysmal dilatation, and stenosis. Surgery 1973;74:931-944.
8.
Almanaseer Y, Rosman HS, Kazmouz G, Giraldo AA, Martin J: Severe dilatation of saphenous vein grafts: a late complication of coronary surgery in which the diagnosis is suggested by chest x-ray. Cardiology 2005;104:150-155.
9.
Chung MM, Chan YC, Law Y, Cheng SW: Infectious anastomotic pseudoaneurysm complicating renal allograft: case report and review of literature. Int J Nephrol Renovasc Dis 2017;10:55.
10.
Dean RH, Wilson JP, Burko H, Foster JH: Saphenous vein aortorenal bypass grafts: serial arteriographic study. Ann Surg 1974;180:469.
11.
Rundback JH, Rizvi A, Rozenblit GN, Poplausky M, Maddineni S, Crea G, et al: Percutaneous stent-graft management of renal artery aneurysms. J Vasc Int Radiol 2000;11:1189-1193.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.